Pharmaceuticals, Biotechnology and Life Sciences
Stemedica Cell Technologies today announced positive results from its Phase I/IIa clinical study for the treatment of ischemic stroke.
Allergan announced positive 3-month topline results from the second pivotal clinical trial of Bimatoprost SR, a first-in-class sustained-release, biodegradable implant for the reduction of IOP in patients with open-angle glaucoma or ocular hypertension, while the global pharmaceutical leader noted the positive results from the first Phase 3 trial were reported in June 2018.
A Dutch maker of of transformative RNA medicines for the treatment of severe genetic rare diseases, ProQR Therapeutics, has got the U.S. Food and Drug Administration (FDA) tips for a Phase 2/3 pivotal trial Illuminate for sepofarsen, in patients with Leber’s congenital amaurosis 10 (LCA10) due to the p.Cys998X mutation in the CEP290 gene, the leading genetic cause of childhood blindness.
Galapagos has discovered GLPG3312, a first generation compound against a novel and undisclosed inflammation target class, and it started Phase 1 trial.
Basilea Pharmaceutica posted preliminary revenue for the financial year 2018, which is expected to increase by 31% over 2017 to about CHF133 million (€118.37M), from the last year’s CHF101.5 million (€90.3M).
Axsome Therapeutics’ AXS-05, a novel, oral, investigational NMDA receptor antagonist with multimodal activity, met the prespecified primary endpoint and significantly improved symptoms of depression in the ASCEND Phase 2 trial in major depressive disorder (MDD), the company said Monday.
Adverum Biotechnologies, a California-based ophthalmology and rare diseases focused biotech company, expects to provide an update on enrollment from the OPTIC phase 1 clinical trial in the first half of 2019, and interim data on the three cohorts from the OPTIC phase 1 clinical trial by the first quarter of 2020, it said in an outlook for 2019.
New York-based cancer therapeutics company, Stelexis Therapeutics has closed a $43 million Series A financing to expand its proprietary platform to discover and selectively target pre-cancerous stem cells.
AstraZeneca has reached a clinical development milestone with immuno-oncology candidate AZD4635, thus triggering a $15 million payment to its partner, Sosei Group.
4D pharma and The University of Texas MD Anderson Cancer Center will together work on testing 4D’s Live Biotherapeutic oncology pipeline across a range of cancer settings, the company said on Monday in a press release